RESUMO
Introduction: The pulmonary artery pulsatility index (PAPI) is a newer hemodynamic index used for assessment of right ventricular performance. We hypothesized that PAPI predicts morbidity and mortality in acute systolic heart failure (HF). Methods: The ESCAPE trial was utilized to identify the prognostic value of PAPI at different time points in patients hospitalized with acute systolic HF who received care assisted with central hemodynamic monitoring. Results: Among 167 patients (age 57 years, 71% men), PAPI significantly increased from admission to optimum hemodynamic day (from 2.88 to 4.09, P < 0.001) and final day (from 3.24 to 3.91, P = 0.032), and the magnitude of increase was strongly associated with markers of decongestion. Discharge PAPI was higher among survivors compared to non-survivors (median 3.1 vs. 2.0, P = 0.0008) and among patients who did not require rehospitalization compared to re-hospitalized patients (median 3.33 vs. 2.67, P = 0.017), both at 6-months. Discharge PAPI predicted mortality with AUC of 0.631 (P = 0.0207), rehospitalization (AUC 0.598, P = 0.0303), and composite of death, rehospitalization, cardiac transplant (AUC 0.621, P = 0.0101). An optimal cutoff value of discharge PAPI ≤2 had the highest sensitivity and specificity in predicting 6-month mortality, rehospitalization and the composite endpoint. Discharge PAPI, had a higher (though non-significant) AUC in predicting death and composite endpoint compared to admission PAPI, next day PAPI and optimal day PAPI. Cox proportional hazard analysis showed that discharge PAPI remained an independent predictor of the composite endpoint (hazard ratio 0.890, 95% CI 0.819-0.967, P = 0.006) after covariate adjustment. Conclusions: Discharge PAPI ≤2 is a marker of intermediate-term morbidity and mortality in acute systolic HF.
RESUMO
Anatomical SYNTAX score (SS1) and SYNTAX score II (SS2) are often utilized to determine the optimal revascularization strategy. Although US veterans have unique characteristics that may affect outcomes after revascularization, the prognostic values of SS1 and SS2 in veterans have not yet been validated. We performed a retrospective analysis of consecutive veteran patients who underwent percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) for left main and/or 3-vessel disease from 2009 to 2014. SS1 and SS2 were calculated for each patient. The primary outcome was all-cause mortality. The prognostic values of SS1 and SS2 were compared by receiver operating characteristic curve analysis. The predicted 4-year mortality derived from SS2 was compared with the observed 4-year mortality estimated from Kaplan-Meier analysis. After exclusion, 286 patients (99% male) were included. Among 286 patients, 79 patients (27.6%) had left main disease, 151 (52.8%) underwent PCI, and 135 (47.2%) underwent CABG. Overall mortality was 27.6% at a median follow-up of 5.0 years. SS2 had better discriminative ability for all-cause mortality than SS1 (c-index 0.79 vs 0.52, p <0.001). Observed and predicted 4-year mortality correlated well in patients with low and intermediate SS2 in both PCI and CABG cohorts, but observed mortality was higher than predicted in the PCI cohort with high SS2 (observed 54.7% vs predicted 40.5%). In conclusion, observed and predicted 4-year mortality derived from SS2 correlated well in patients with low and intermediate SS2, but SS2 underestimated mortality in the PCI cohort with high SS2.
